YAYINLAR

A1. Topuz E, Eralp Y, Saglam S, Saip P, Aydiner A, Berkman S, Yavuz E. “Efficacy of intraperitoneal cisplatin as consolidation therapy in patients with pathologic complete remission following front-line therapy for epithelial ovarian cancer. Consolidative intraperitoneal cisplatin in ovarian cancer.”Gynecol Oncol. 92(1): 147–5, 2004.

A2. Balci NC, Akun E, Erturk M, Saglam S, Inan N, Balci Y. “Renal-related perinephric fluid collections: MRI findings.” Magn Reson Imaging. 23(5): 679–84, 2005.

A3. Basaran M, Bavbek ES, Saglam S, Eralp L, Sakar B, Atalar AC, Bilgic B, Ozger H, Onat H. “A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas.” Oncology. 72(3–4): 255–60, 2007.

A4. Sakar B, Gumus M, Basaran M, Argon A, Ustuner Z, Ustaoglu MA, Saglam S, Guney N, Tenekeci AN, Aykan NF. “XELOX followed by XELIRI or the reverse sequence in advanced colorectal cancer.” Oncology. 73(5–6): 298–304, 2007.

A5. Topuz E, Derin D, Can G, Kürklü E, Cinar S, Aykan F, Cevikbaş A, Dişçi R, Durna Z, Sakar B, Saglam S, Tanyeri H, Deniz G, Gürer U, Taş F, Guney N, Aydiner A. “Effect of oral administration of kefir on serum proinflammatory cytokines on 5-FU induced oral mucositis in patients with colorectal cancer.” Invest New Drugs. 26(6): 567–72, 2008.

A6. Balci NC, Befeler AS, Bieneman BK, Fattahi R, Saglam S, Havlioglu N. “Fat containing HCC: findings on CT and MRI including serial contrast-enhanced imaging.” Acad Radiol. 16(8): 963–8, 2009.

A7. Balci NC, Perman WH, Saglam S, Akisik F, Fattahi R, Bilgin M. “Diffusion-weighted magnetic resonance imaging of the pancreas.” Top Magn Reson Imaging. 20(1): 43–7, 2009.

A8. Saglam S, Suzme R, Gurdol F. “Serum tumor necrosis factor-alpha and interleukin-2 concentrations in newly diagnosed ERBB2 (HER2/neu) positive breast cancer patients.” Int J Biol
Markers. 24(3): 142–6, 2009.

A9. Balik E, Asoglu O, Saglam S, Yamaner S, et al. Effects of surgical laparoscopic experience on the short-term postoperative outcome of rectal cancer: results of a high volume single center institution. Surg Laparosc Endosc Percutan Tech. 2010 Apr;20(2):93-9.

A10. Bitisik O, Saip P, Saglam S, Derin D, Dalay N. Mammaglobin and maspin transcripts in blood may reflect disease progression and the effect of therapy in breast cancer. Genet Mol Res. 2010;9:97-106.

A11. Saglam S,Aykan NF,Şakar B et al. A pilot study evaluating the safety and toxicity of epirubicin, cisplatin, and UFT (ECU regimen) in advanced gastric carcinoma. Journal of Gastrointestinal Oncology.2; 219-26, 2011

A12. Engin G, Sharifov R, Güral Z, Sağlam EK, Sağlam S, et al.Can diffusion-weighted MRI determine complete responders after neoadjuvant chemoradiation for locally advanced rectal cancer? Diagn Interv Radiol. 2012 ;18:574-81

A13. Keskin S, Yıldız I, Sen F, Aydogan F, Kilic L, Ekenel M, Saglam S, et al. Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC).Clin Transl Oncol. 2013 ;15:403-8.

A14. Karanlik H, Kurt A, Kunduz E, Serin K, Saglam S, et al.Effects of intraperitoneal bevacizumab administration on colonic anastomosis and early postoperative adhesion formation. Surg Innov. 2013 ;20:559-65.

A15. Saglam S, Arifoglu A, Saglam EK, Tunca F, et al. Neoadjuvant hyperfractionated-accelerated radiotherapy with concomitant chemotherapy in esophageal cancer: phase II study. J Gastrointest Oncol. 2013 ;4:380-7.

A16. Saglam S, Bugra D, Saglam EK, Asoglu O, et al. Fourth versus eighth week surgery after neoadjuvant radiochemotherapy in T3-4/N0+ rectal cancer: Istanbul R-01 study. J Gastrointest Oncol. 2014 ;5:9-17

A17. Alco G, Igdem S, Dincer M, Ozmen V, Saglam S, et al. Vitamin D levels in patients with breast cancer: importance of dressing style. Asian Pac J Cancer Prev. 2014;15:1357-62

A18. Pilanci KN, Ordu C, Akpinar H, Balci C, Başsülü N, Köksal UI, Elbüken F, Okutur K, Bülbül G, Sağlam S, Demir G. Dramatic Response to Catumaxomab Treatment for Malign Ascites
Related to Renal Cell Carcinoma With Sarcomotoid Differentiation. Am J Ther. 2014 Apr 11. [Epub ahead of print]

A19. Akgun Z, Saglam S, Yucel S, Gural Z, Balik E, et al. Neoadjuvant chronomodulated capecitabine with radiotherapy in rectal cancer: a phase II brunch regimen study. Cancer Chemother Pharmacol. 2014 ;74:751-6

A20. Tanriverdi O, Kaytan-Saglam E, Ulger S, Bayoglu IV, Turker I, Ozturk-Topcu T, Cokmert S, Turhal S, Oktay E, Karabulut B, Kilic D, Kucukzeybek Y, Oksuzoglu B, Meydan N, Kaya V, Akman T, Ibis K, Saynak M, Sen CA, Uysal-Sonmez O, Pilancı KN, Demir G, Saglam S, Kocar M, Menekse S, Goksel G, Yapar-Taskoylu B, Yaren A, Uyeturk U, Avci N, Denizli B, Ilis-Temiz E. The clinical and pathological features of 133 colorectal cancer patients with brain metastasis: a multicenter retrospective analysis of the Gastrointestinal Tumors Working Committee of the Turkish Oncology Group (TOG).Med Oncol. 2014 ;31:152.

A21. Kaytan Saglam E, Yucel S, Balik E, Saglam S, Asoglu O, Yamaner S et al. Adjuvant chemoradiotherapy after D2 resection in gastric cancer: a single-center observational study. J Cancer Res Clin Oncol. 2015 Feb;141(2):361-7

A22. Ordu C, Pilanci KN, Koksal UI, Okutur K, Saglam S, Tecimer C, Demir G.Can megestrol acetate induce thrombosis in advanced oncology patients receiving chemotherapy?
Asian Pac J Cancer Prev. 2014;15(23):10165-9.

A23. Ozkan ZG, Poyanli A, Ucar A, Kuyumcu S, Akyuz F, Keskin S, Saglam S, et al .Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis. Cancer Biother Radiopharm. 2015 Apr;30(3):132-8.

A24. Celebi F, Pilanci KN, Saglam S, Balci NC.Primary renal angiosarcoma with progressive clinical course despite surgical and adjuvant treatment: A case report.Oncol Lett. 2015 Apr;9(4):1937-1939.

A25. Koksal UI, Pilanci KN, Ordu C, Okutur K, Saglam S, Demir G. Trichomegaly Induced by Cetuximab: Case Series and Review the Literature.Am J Ther. 2015 Jun 15.

A26. Serin KR, Gultekin FA, Batman B, Ay S, Kapran Y, Saglam S, Asoglu O.Robotic versus laparoscopic surgery for mid or low rectal cancer in male patients after neoadjuvant chemoradiation therapy: comparison of short-term outcomes.J Robot Surg. 2015 Sep;9(3):187-94

A27. Saglam S, Hacisahinogullari H, Ozturk N, Kapran Y, et al.Outcomes of first-line long-acting octreotide treatment in non-functional, advanced gastroenteropancreatic neuroendocrine tumors.J BUON. 2015 Sep-Oct;20(5):1201-5.

A28. Ozturk Sari S, Taskin OC, Gundogdu G, Yegen G, Onder S, Keskin M, Saglam S, et al.The Impact of Phosphohistone-H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic Neuroendocrine Tumors.Endocr Pathol. 2016 Mar 2.

A29. Pilancı KN, Saglam S, Okyar A, et al. Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study.Cancer Chemother Pharmacol. 2016 Jul;78(1):143-50.

A30. Saglam S.Watch-and-wait versus surgical resection for patients with rectal cancer.
Lancet Oncol. 2016 Apr;17(4):e132. doi: 10.1016/S1470-2045(16)00008-5.


B1. Saglam S, Bugra D, Kaytan Saglam E, Yamaner S, Asoglu O, Balik E, Oral E.N, Sakar B, Kizir A, Kapran Y, Camlıca H. “Prospective randomized study comparing fourth-week surgery versus eighth- week surgery after neoadjuvant concomitant radiotherapy and infusional 5-FU in T3-4/N0+ rectal cancer: Istanbul R-01 Study”. J Clin Oncol 27:15s, (suppl; abstr 4131), 2009

B2. Saglam S, Arifoglu A, Saglam EK, Asoglu O, Yamaner S. “Induction chemotherapy plus concurrent chemoradiotherapy (HART) sor squamous cell carcinoma of the esophagus: Preliminary analysis of the phase II trial”. Proc. ASCO GI Annual Meeting of the American Society of Clinical Oncology, Gastrointesitinal Cancer, USA, abstr no: 75, 2008.

B3. Sakar B, Gumus M, Argon A, Guney N, Saglam S, Basaran M, Ustaoglu M.A, Ustuner Z, Aykan F. “XELOX followed by XELIRI or the reverse sequence in advanced colorectal cancer”. Proc. ASCO GI Annual Meeting of the American Society of Clinical Oncology, Gastrointesitinal Cancer, USA, abstr no: 307, 2007

B4. Saglam S. “Epirubicine, cisplatin, UFT (ECU Regimen) in advanced gastric carcinoma”. Proc. ASCO GI Annual Meeting of the American Society of Clinical Oncology, Gastrointesitinal Cancer, USA, abstr no:86, 2006.

B5. Balik E, Bektas H, Yamaner S, Bugra D, Bulut T, Saglam S, Saglam E, Akyuz A, Buyukuncu A, Sokucu N. “The effects of neoadjuvant chemo-radiotherapy on the complication rates in rectal cancer surgery”. XXI. Biennial Congress of International Society of The University of Colon and Rectal Surgeons 25-28 June, ABD, Abstr no: 93, 2006

B6. Balik E, Bektas H, Keskin M, Bugra D, Yamaner S, Bulut T, Saglam S, Saglam E, Sokucu N, Buyukuncu Y, Akyuz A. “Surgical timing for rectal cancer operation after neoadjuvant radiotherapy and chemotherapy”. XXI. Biennial Congress of International Society of The University of Colon and Rectal Surgeons 25-28 June, ABD, Abstr no: 95, 2006

B7. Bitisik O, Saip P, Saglam S, Dalay N. “Detection of circulating breast cancer cells in relation to therapy” Journal of Clinical Oncology, ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supp. abstr no:689), 2005.

B8. Sakar B, Aykan N.F, Saglam S, Ustuner Z. “Long-term survival after curative resection for pancreatic ductal adenocarcinoma” Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supp. Abstr no: 4227), 2004.

B9. 1141PD Gasroenteropancreatic Neuroendocrine Tumors (GEPNET) Registry :Update from an International Collaboration . S Yalcin, S Glasberg, H Abali, F Aykan, L Bai, J Kattan, HY Lim, YS Park, H Raef, J Ramos, K Rau, S Saglam, S Serdengecti, A Sevinc, Y Shan, Y Shyr, V Sriuranpong, SN Turhal, K Yeh, T Hwang. Annals of Oncology.2014/9/125 suppl 4 iv398-iv398


C1. Rejin Kebudi, Saglam S “Hypertrophic Osteoarthropathy”, p954. Encyclopedia of Molecular Mechanisms of Disease Lang, Florian (Ed.) Version: print (book) Springer 3 volume, 2009.

C2. Blood Irradiation.Saglam S, Aydin Cakir, Seyfettin Kuter.2011/11
Modern Approaches To Quality Control.p335-346.InTech

C3.Gastric Cancer ;AME Publishing 2015; A pilot study evaluating the safety and toxicity of epirubicin, cisplatin, and UFT (ECU regimen) in advanced gastric carcinoma


D1. Saglam S. “Sinyal Iletisini Bloke eden Monoklonal Antikorlar [cd 20 (rituksimab), Her 1 Blokerleri (setuksimab, Panitumumab, Matuzumab, Nimotuzumab), Her 2 Blokerleri (trastuzumab), Her-1-2 Blokeri (pertuzumab), Igr-1r, Vegf (bevasizumab), Vegf Trap, Vegfr1, Vegfr2, Trail R1 (mapatumumab), Trail R2 (leksatumumab), Pdgf-alfa Integrinler]”. Türkiye Klinikleri Dergisi/Tıbbi Onkoloji- Onkolojide Yeni İlaç Tedavileri Özel Sayısı; Cilt/Vol: 2 (1), 37-44, 2009.

D2. Saglam S, AYKAN N.F. “Nöroendokrin Tümörlerin Tedavisi” Derleme (Review). Endokrinolojide Diyalog; vol: 2, 142- 6, 2007.

D3. Uçar A, Yekeler E, Yıldırım Dönmez F, Tunacı M, Saglam S, Acunaş G. “Sternal Metastazlı Uterus Liomyosarkomu” İstanbul Tıp Fakültesi Mecmuası; Cilt: 68 (3), 078-080, 2005.

D4. Kuter S, Saglam S. “Transfüzyon kaynaklı graft-versus-host hastalığını önlemede kullanılan kan ve kan bileşenleri, ışınlama cihazlarının fiziksel yapısı, radyasyon dozları, dozimetrik ölçümler, ışınlama dozları ve klinik endikasyonlar”.Türk Onkoloji Dergisi, Cilt: 24 (3), 2009


E1. Topuz E, Eralp Y , Saglam S, Saip P, Aydıner A, Berkman S, Yavuz E, “Primer kemoterapi sonrası tam remisyon sağlanan over kanserli hastalarda konsolidasyon tedavisi olarak intraperitoneal sisplatin tedavisinin etkinliği”, 15. Ulusal Kanser Kongresi, P 310, Antalya, 2003.

E2. Balık E, Keskin M, Bektaş H, Saglam S, Sağlam E, Buğra D, Yamaner S, Bulut T, Sökücü N, Büyükuncu Y, Akyüz A. “Neoadjuvan kemoradyoterapi sonrası 4. ve 8. haftasında ameliyat edilen rektum kanserli hastaların erken ve geç dönem komplikasyonları açısından karşılatırılması”. Ulusal Cerrahi Kongresi, 24-28 Mayıs, Antalya, 2006

E3. Balık E, Keskin M, Bektaş H, Saglam S, Sağlam E, Yamaner S, Buğra D, Bulut T, Büyükuncu Y, Sökücü N, Akyüz A. “Rektum kanserinde neoadjuvan kemoradyoterapinin perop ve erken dönem komplikasyonlar üzerine etkisi”. Ulusal Cerrahi Kongresi, 24-28 Mayıs, Antalya, 2006.

E4. Saglam S, Başaran M, Onat H, Bavbek S.”Primer gastrik lenfomalı hastalarda gastrektominin sağkalıma etkisi”. 1.Tıbbı Onkoloji Kongresi, 29 Mart – 2 Nisan, Antalya, abstr no: 213, 2006.

E5. Saglam S, Aykan F, Şakar B, Yazar A. “İleri evre mide kanserinde epirubicine, cisplatin, UFT (ECU Rejimi)” 1.Tıbbı Onkoloji Kongresi, 29 Mart – 2 Nisan, sözel bildiri 5, Antalya, 2006.

E6. Ergen A, Saglam S, Almaç Z, Tuncer S, Peksayar G. “Karsinoid tümör ve orbita metastazı: Olgu sunumu” XII. Ulusal Kanser Kongresi, P 629,Antalya, 2007.

E7. Vural S, Karadağ Ç. A. Tanık C, Saglam S, Karaman S, Urgancı N, Erdem E.” Epididim metastazlı çocukluk çağı kolon adenokarsinomu: Olgu sunumu” XIII. Ulusal Kanser Kongresi, P
330, Antalya, 2009.


Fa: Ulusal Kitap Editörlüğü
F1a. Saglam S. “Kemoterapi için Kaynak Kılavuz El Kitabı: Companion Handbook to the Chemotherapy Sourcebook” Lippincott Williams&Wilkins Michael C. Perry (çeviri). İstanbul Medikal Yayıncılık, 534 sayfa, 2008.

Fb: Ulusal Kitap Bölümü
F1b. Saglam S. “Kanser Hastalıklarında Destek Tedavi” İç hastalıkları, Editör Prof Dr Enver Dolar, Nobel&Güneş Yayınevi Bölüm 7/174, 2005